-
Je něco špatně v tomto záznamu ?
Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
SD. Anker, J. Butler, MS. Usman, G. Filippatos, JP. Ferreira, E. Bocchi, M. Böhm, HPB. Rocca, DJ. Choi, V. Chopra, E. Chuquiure, N. Giannetti, JE. Gomez-Mesa, S. Janssens, JL. Januzzi, JR. González-Juanatey, B. Merkely, SJ. Nicholls, SV. Perrone,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- benzhydrylové sloučeniny terapeutické užití škodlivé účinky MeSH
- funkce levé komory srdeční MeSH
- glifloziny * terapeutické užití MeSH
- glukosidy terapeutické užití škodlivé účinky MeSH
- lidé MeSH
- srdeční selhání * farmakoterapie MeSH
- tepový objem MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF) > 40%. Here, we report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (≥ 50%) (n = 4,005; 66.9%) or mid-range (41-49%). In patients with LVEF ≥ 50%, empagliflozin reduced the risk of cardiovascular death or HHF (the primary endpoint) by 17% versus placebo (hazard ratio (HR) 0.83; 95% confidence interval (CI): 0.71-0.98, P = 0.024). For the key secondary endpoint, the HR for total HHF was 0.83 (95%CI: 0.66-1.04, P = 0.11). For patients with an LVEF of 41-49%, the HR for empagliflozin versus placebo was 0.71 (95%CI: 0.57-0.88, P = 0.002) for the primary outcome (Pinteraction = 0.27), and 0.57 (95%CI: 0.42-0.79, P < 0.001) for total HHF (Pinteraction = 0.06). These results, together with those from the EMPEROR-Reduced trial in patients with LVEF < 40%, support the use of empagliflozin across the full spectrum of LVEF in heart failure.
1st Department of Medicine Faculty of Medicine Mannheim University of Heidelberg Mannheim Germany
Argentine Catholic University Buenos Aires Argentina
Baylor Scott and White Research Institute Dallas TX USA
Boehringer Ingelheim International Ingelheim Germany
Boehringer Ingelheim Pharma GmbH and Co KG Biberach Germany
Boehringer Ingelheim Pharmaceuticals Inc Ridgefield CT USA
Cardiology Department University Hospital CIBERCV Santiago de Compostela Spain
Cardiology Service Fundación Valle del Lili Universidad Icesi Cali Cali Colombia
Cardiovascular Department Cardiology Division Papa Giovanni XXIII Hospital Bergamo Italy
Central Michigan University Mount Pleasant MI USA
Department of Cardiology partner site Berlin Charité Universitätsmedizin Berlin Berlin Germany
Department of Cardiovascular Diseases University Hospitals Leuven Leuven Belgium
Department of Cardiovascular Medicine Faculty of Medical Sciences Kyushu University Fukuoka Japan
Department of Medicine Seoul National University Bundang Hospital Seoul South Korea
FLENI and IADT Institute Buenos Aires Argentina
Heart and Vascular Center Semmelweis University Budapest Hungary
Institute of Heart Diseases Wrocław Medical University Wrocław Poland
London School of Hygiene and Tropical Medicine London UK
Maastricht University Medical Center Maastricht the Netherlands
Massachusetts General Hospital and Baim Institute for Clinical Research Boston MA USA
Max Superspeciality Hospital Saket New Delhi India
McGill University Health Centre Montreal Quebec Canada
National and Kapodistrian University of Athens School of Medicine Athens Greece
National Heart Centre Singapore Singapore Singapore
National Institute of Cardiology Mexico City Mexico
NIHR Biomedical Research Centre University of Leicester Glenfield Hospital Leicester UK
School for Cardiovascular Disease CARIM Maastricht the Netherlands
St Michael's Hospital University of Toronto Toronto Ontario Canada
Universitätsklinikum des Saarlandes Homberg Saar Germany
Université de Lorraine INSERM INI CRCT CHRU Nancy France
University and Emergency Hospital Bucharest Romania
University of Medicine and Pharmacy Carol Davila Bucharest Romania
University of Mississippi Jackson MS USA
University of Mississippi Medical Center Jackson MS USA
Victorian Heart Institute Monash University Melbourne Victoria Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004921
- 003
- CZ-PrNML
- 005
- 20230425171810.0
- 007
- ta
- 008
- 230418s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41591-022-02041-5 $2 doi
- 035 __
- $a (PubMed)36471037
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Anker, Stefan D $u Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany. s.anker@cachexia.de $u Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland. s.anker@cachexia.de $1 https://orcid.org/0000000208058683
- 245 10
- $a Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved / $c SD. Anker, J. Butler, MS. Usman, G. Filippatos, JP. Ferreira, E. Bocchi, M. Böhm, HPB. Rocca, DJ. Choi, V. Chopra, E. Chuquiure, N. Giannetti, JE. Gomez-Mesa, S. Janssens, JL. Januzzi, JR. González-Juanatey, B. Merkely, SJ. Nicholls, SV. Perrone, IL. Piña, P. Ponikowski, M. Senni, D. Sim, J. Spinar, I. Squire, S. Taddei, H. Tsutsui, S. Verma, D. Vinereanu, J. Zhang, T. Iwata, JM. Schnee, M. Brueckmann, SJ. Pocock, F. Zannad
- 520 9_
- $a The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF) > 40%. Here, we report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (≥ 50%) (n = 4,005; 66.9%) or mid-range (41-49%). In patients with LVEF ≥ 50%, empagliflozin reduced the risk of cardiovascular death or HHF (the primary endpoint) by 17% versus placebo (hazard ratio (HR) 0.83; 95% confidence interval (CI): 0.71-0.98, P = 0.024). For the key secondary endpoint, the HR for total HHF was 0.83 (95%CI: 0.66-1.04, P = 0.11). For patients with an LVEF of 41-49%, the HR for empagliflozin versus placebo was 0.71 (95%CI: 0.57-0.88, P = 0.002) for the primary outcome (Pinteraction = 0.27), and 0.57 (95%CI: 0.42-0.79, P < 0.001) for total HHF (Pinteraction = 0.06). These results, together with those from the EMPEROR-Reduced trial in patients with LVEF < 40%, support the use of empagliflozin across the full spectrum of LVEF in heart failure.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a benzhydrylové sloučeniny $x terapeutické užití $x škodlivé účinky $7 D001559
- 650 _2
- $a glukosidy $x terapeutické užití $x škodlivé účinky $7 D005960
- 650 12
- $a srdeční selhání $x farmakoterapie $7 D006333
- 650 12
- $a glifloziny $x terapeutické užití $7 D000077203
- 650 _2
- $a tepový objem $7 D013318
- 650 _2
- $a funkce levé komory srdeční $7 D016277
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Butler, Javed $u Baylor Scott and White Research Institute, Dallas, TX, USA $u University of Mississippi, Jackson, MS, USA
- 700 1_
- $a Usman, Muhammad Shariq $u University of Mississippi Medical Center, Jackson, MS, USA
- 700 1_
- $a Filippatos, Gerasimos $u National and Kapodistrian University of Athens School of Medicine, Athens, Greece
- 700 1_
- $a Ferreira, João Pedro $u Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France $u Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal
- 700 1_
- $a Bocchi, Edimar $u Heart Failure Clinics, Instituto do Coracao, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
- 700 1_
- $a Böhm, Michael $u Universitätsklinikum des Saarlandes, Homberg/Saar, Germany
- 700 1_
- $a Rocca, Hans Pieter Brunner-La $u Maastricht University Medical Center, Maastricht, the Netherlands $u School for Cardiovascular Disease CARIM, Maastricht, the Netherlands
- 700 1_
- $a Choi, Dong-Ju $u Department of Medicine, Seoul National University Bundang Hospital, Seoul, South Korea
- 700 1_
- $a Chopra, Vijay $u Max Superspeciality Hospital, Saket, New Delhi, India
- 700 1_
- $a Chuquiure, Eduardo $u National Institute of Cardiology, Mexico City, Mexico
- 700 1_
- $a Giannetti, Nadia $u McGill University Health Centre, Montreal, Quebec, Canada
- 700 1_
- $a Gomez-Mesa, Juan Esteban $u Cardiology Service, Fundación Valle del Lili, Universidad Icesi Cali, Cali, Colombia
- 700 1_
- $a Janssens, Stefan $u Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a Januzzi, James L $u Massachusetts General Hospital and Baim Institute for Clinical Research, Boston, MA, USA $1 https://orcid.org/0000000283381798
- 700 1_
- $a González-Juanatey, José R $u Cardiology Department, University Hospital, CIBERCV, Santiago de Compostela, Spain
- 700 1_
- $a Merkely, Bela $u Heart and Vascular Center, Semmelweis University, Budapest, Hungary $1 https://orcid.org/0000000165140723
- 700 1_
- $a Nicholls, Stephen J $u Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia
- 700 1_
- $a Perrone, Sergio V $u Argentine Catholic University, Buenos Aires, Argentina $u FLENI & IADT Institute, Buenos Aires, Argentina
- 700 1_
- $a Piña, Ileana L $u Central Michigan University, Mount Pleasant, MI, USA $1 https://orcid.org/0000000249867129
- 700 1_
- $a Ponikowski, Piotr $u Wrocław Medical University, Wrocław, Poland
- 700 1_
- $a Senni, Michele $u Cardiovascular Department, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo, Italy
- 700 1_
- $a Sim, David $u National Heart Centre Singapore, Singapore, Singapore
- 700 1_
- $a Spinar, Jindrich $u Internal Cardiology Department, St Ann University Hospital and Masaryk University Brno, Brno, Czech Republic
- 700 1_
- $a Squire, Iain $u NIHR Biomedical Research Centre, University of Leicester, Glenfield Hospital, Leicester, UK
- 700 1_
- $a Taddei, Stefano $u Università di Pisa, Pisa, Italy
- 700 1_
- $a Tsutsui, Hiroyuki $u Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- 700 1_
- $a Verma, Subodh $u St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Vinereanu, Dragos $u University of Medicine and Pharmacy Carol Davila, Bucharest, Romania $u University and Emergency Hospital, Bucharest, Romania $1 https://orcid.org/0000000290548779
- 700 1_
- $a Zhang, Jian $u Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
- 700 1_
- $a Iwata, Tomoko $u Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- 700 1_
- $a Schnee, Janet M $u Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA
- 700 1_
- $a Brueckmann, Martina $u Boehringer Ingelheim International, Ingelheim, Germany $u First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany $1 https://orcid.org/0000000312150746
- 700 1_
- $a Pocock, Stuart J $u London School of Hygiene and Tropical Medicine, London, UK
- 700 1_
- $a Zannad, Faiez $u Université de Lorraine, INSERM INI-CRCT, CHRU, Nancy, France $1 https://orcid.org/0000000174561570 $7 xx0065029
- 773 0_
- $w MED00003459 $t Nature medicine $x 1546-170X $g Roč. 28, č. 12 (2022), s. 2512-2520
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36471037 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425171806 $b ABA008
- 999 __
- $a ok $b bmc $g 1925173 $s 1191130
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 28 $c 12 $d 2512-2520 $e 20221205 $i 1546-170X $m Nature medicine $n Nat Med $x MED00003459
- LZP __
- $a Pubmed-20230418
